After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything
Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattle’s Wells Fargo Building. Louis Picker and Klaus Früh, professors at...
BIO: What’s the ROI on a COVID-19 vaccine? We have no idea, says Pfizer
John Young, Pfizer’s chief business officer, was only about four minutes into a one-hour fireside chat at this year’s virtual BIO conference when he addressed a question that’s been weighing on investors for several weeks now: If the company successfully develops a...
Coronavirus tracker: T cells could provide hint to how Roche’s Actemra treats COVID-19 patients
A new study out of China has tied T cell activation to Roche’s IL-6 inhibitor Actemra, which has shown some early effect in treating cytokine storm in severe COVID-19 patients. Meanwhile, the National Institutes of Health has kicked off a “Shark...
Blue Cross MN CEO: Why COVID-19 may be making the case for value-based care
COVID-19 is making the case for accelerating the move to more value-based models of care. Hospitals’ financial struggles as they pause elective procedures during the pandemic highlight the weaknesses in a volume-based system, said Craig Samitt, M.D., CEO of...
Global clinical trials take a major hit from pandemic, with endocrine targeted tests worst hit
Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit. This is according to a new breakdown from Medidata (PDF), now owned by Dassault Systèmes, which aims to show by numbers how the COVID-19...LATEST NEWS
More anti-epidemic measures eased today
Bulgaria resumes the “green corridor” walk-in vaccination scheme
30,000 Bulgarians receive jabs against Covid-19 in last three days
CureVac’s mRNA coronavirus shot boasts one advantage over Pfizer and Moderna counterparts—refrigerated storage
COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst